Mississauga, ON -- (SBWire) -- 01/21/2014 --AllPennyStocks.com Media, Inc. (http://www.AllPennyStocks.com/) announces its latest article titled “Arno Therapeutics Hits Milestone by Commencing Third Clinical Trial for Cancer.”
Companies mentioned in this article include Arno Therapeutics, Inc. (OTCQB:ARNI).
Article Excerpt:
According to the American Cancer Society, approximately 49,500 cases of endometrial cancer were diagnosed in 2013 and about 8,200 women would die from the disease. Interestingly, a study by researchers at the University of Minnesota was published in the online version of Cancer Epidemiology, Biomarker and Prevention in December that showed women who consume a large amount of sugared beverages are at a higher risk to develop Type 1, but not Type 2, endometrial cancer. Estrogen-dependent Type 1 endometrial cancer, often called uterine cancer (although there are several types of uterine cancer), is the most common form of the disease. It is most frequently diagnosed in women over the age of 55.
New Jersey-based Arno Therapeutics, Inc. (OTCQB:ARNI) is developing new products for the treatment of a spectrum of cancers through a licensing agreement giving them development and marketing rights for three innovative products, onapristone, AR-42 and AR-12.
The full version of this article can be found at:
http://www.allpennystocks.com/aps_us/special-reports/421/arno-therapeutics-hits-milestone-by-commencing-third-clinical-trial-for-cancer.htm
About AllPennyStocks.com
AllPennyStocks.com is focused on the small-cap / penny stock market and has become a reputable name in the investment community. AllPennyStocks.com runs a Canadian and US site to provide investors in Canada as well as the United States with informative and unique content and information. AllPennyStocks.com runs daily technical penny stocks to watch, has a daily market write-up, provides company spotlights, runs unique most active pages strictly for penny stocks trading on the TSX, TSX Venture, NASDAQ and OTC BB, and much more information for the average investor.
AllPennyStocks.com also runs an email newsletter that aims to uncover stocks that are still under the radar of most investors. Criteria AllPennyStocks.com looks for includes strong revenues, a seasoned management, innovative business plans, among many others. AllPennyStocks.com also looks for companies that announce breaking news, recent 52-week highs/lows, technical breakouts, and other favorable corporate information.
Investors are encouraged to subscribe to the AllPennyStocks.com FREE e-mail newsletter and see what tens of thousands of other investors have already been receiving since 1999. Investors can receive their free newsletter subscription by clicking here: http://www.allpennystocks.com/aps_common/newsletter_free.asp.
Contact
AllPennyStocks.com Media, Inc.
Peter Szafranski -- President
Phone: (905) 361-5680
E-Mail: peter@allpennystocks.com
Websites: http://www.allpennystocks.com / http://www.bullishinvestor.com
Note: AllPennyStocks.com has not received compensation for carrying the above-mentioned company; a full disclaimer can be viewed here: http://www.allpennystocks.com/aps_common/disclaimer.asp.
All Penny Stocks.com News: Arno Therapeutics Hits Milestone by Commencing Third Clinical Trial for Cancer